Comparison of short-term outcomes of open, laparoscopic, and robotic surgery for Kasai portoenterostomy in biliary atresia: a 10-year single center study - Takeaways - MDSpire

Comparison of short-term outcomes of open, laparoscopic, and robotic surgery for Kasai portoenterostomy in biliary atresia: a 10-year single center study

  • By

  • Yuliang Jiang

  • Menglei Zhu

  • Jianlei Chen

  • Zhenwei Zhu

  • Haowei Zhao

  • Qi Wang

  • Ziang Wang

  • Jie Zhu

  • Peng Cai

  • April 20, 2026

  • 0 min

Share

  • 1

    This study compares the efficacy and safety of open, laparoscopic, and robotic-assisted Kasai portoenterostomy in biliary atresia patients.

  • 2

    Robotic-assisted Kasai portoenterostomy had a longer operative time compared to laparoscopic and open approaches, with significant differences in duration.

  • 3

    Open Kasai portoenterostomy demonstrated advantages in reducing dissection time and blood loss during surgery compared to minimally invasive techniques.

  • 4

    Minimally invasive approaches, including laparoscopic and robotic-assisted techniques, resulted in faster oral feeding and shorter hospital stays.

  • 5

    All surgical approaches showed comparable short-term outcomes regarding jaundice clearance and one-year survival with native liver.

Original Source(s)

Comparison of short-term outcomes of open, laparoscopic, and robotic surgery for Kasai portoenterostomy in biliary atresia: a 10-year single center study

  • by Yuliang Jiang, Menglei Zhu, Jianlei Chen, Zhenwei Zhu, Haowei Zhao, Qi Wang, Ziang Wang, Jie Zhu, Peng Cai

  • April 20, 2026

Related Content

Layered precision suturing vs. traditional double-layer closure at cesarean: a randomized trial of uterine scar healing and maternal outcomes

Innovative Semi-Rigid Stabilization: Enhancing Precision in Binocular Vision Navigation of the Female Pelvis

FDA Grants Accelerated Approval for OTOF Gene Therapy

A one-time intracochlear gene therapy improved hearing outcomes in patients with OTOF-related sensorineural hearing loss in the phase 1/2 CHORD trial.